brello health semaglutide GLP-1 Unboxing Experience Brello Health Review (2026): Cost,
Description
Life , 12 (1), 29
Consistent with the base-case analysis, sensitivity analyses demonstrated that using GLP-1RAs versus insulin was either cost-saving or cost-effective, except for the analyses where the treatment effectiveness was estimated based on the AT scenario in the second and third sensitivity analyses, showing that a GLP-1RA versus insulin therapy was not cost-effective for averting one case of all-cause death from the payer perspective
Yan Y, Liu B, Du J et al (2021) SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis
becomes a licensing stream
